Nkarta, Inc. Common Stock (NKTX) Stock Price, Quote & AI Analysis
Live NKTX stock price, real-time charts, AI-powered analysis, technical analysis, earnings insights, and market sentiment for Nkarta, Inc. Common Stock.
TradeVae provides AI-driven analysis and real-time market intelligence for Nkarta, Inc. Common Stock (NKTX), including price action, technical indicators, earnings performance, analyst sentiment, and risk-aware market context.
AI Analysis
Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.
Generating AI analysis...
Nkarta, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.
Nkarta, Inc. Common Stock Overview
Company information
Company Overview
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Company Details
Technical Indicators
Key technical analysis metrics and indicators
Loading technical indicators...
Valuation Metrics
Key valuation ratios and comparisons
Loading valuation metrics...
Nkarta, Inc. Common Stock Earnings & Financial Statements
Earnings Calendar
Upcoming earnings dates and historical surprises
Loading earnings calendar...
Financial Statements
Income statements, balance sheets, and cash flow
Loading income statements...
Loading balance sheets...
Loading cash flow statements...